Business Wire

Turkey’s Zer Recognized as “Product Challenger” in Global Procurement Ecosystem

4.4.2022 12:00:00 EEST | Business Wire | Press release

Share

Zer , a Turkey-based company specializing in strategic procurement and sourcing management, has been included – for the first time – on the prestigious Provider Lens™ Quadrant Report of Information Services Group (ISG), a leading global technology research and advisory firm. Updated on a quarterly basis, ISG Provider Lens™ is a practitioner-led service provider comparison, empowered by ISG’s advisory experience and data-driven research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220401005382/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

For the first time, Turkish procurement services firm Zer has been listed on ISG’s Provider Lens™ Quadrant Report (Photo: Business Wire)

A subsidiary of Turkey's Koç Group, Zer took its place in ISG Provider Lens™ report in both the “Procurement BPO Services” and the “Digital Transformation Services” quadrants for both large accounts and midmarket categories. Zer featured in the same quadrant with the firms who consult to industry giants on Fortune 50.

Zer's brand Promena, which is a strategic procurement software, meanwhile, also made the list (in the “Software Platforms and Solutions” quadrant for large accounts), taking a place alongside globally-recognized service providers.

‘Closely followed by procurement professionals’
According to Zer General Manager Mehmet Apak, ISG’s Provider Lens List is extremely influential in the competitive world of digital solutions. “It is closely followed by supply chain and procurement professionals from all over the world,” Apak says. “Lists like ISG Provider Lens™ serve to raise brand awareness in international markets and enhance Turkey's role in the global procurement ecosystem.”

Underlining that global demand for Promena had recently increased by 50%, Apak went on to assert that “Zer’s inclusion in the ISG Provider Lens™ “is a natural reflection of the qualities we bring to all stakeholders – qualities such as resilience and agility.” Both these qualities are crucial, he adds, “in a business environment that is increasingly unpredictable and in which priorities are constantly changing.”

A ‘Value Leader’ in the global procurement sector
Zer‘s strategic procurement software Promena has also been recognized by SpendMatters, Capgemini, Capterra, Procurement Leaders, Art of Procurement and Sourceforge, all of which follow top digital solutions and procurement brands. Since 2019, Promena was included in SpendMatters’ influential Solutionmap Report. Last year, the same report described the company as a “Value Leader” in the global procurement sector.

“We’re pleased that our company is drawing international attention,” Apak says. “In the digital age, procurement and supply chain management is more essential than ever. It lets businesses connect with the rest of the world, keep costs and risks in check, and overcome the hurdles associated with digital transformation.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tülay Genç
support@b2press.com
+90 (212) 635 70 68

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye